{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:30:33Z","timestamp":1793896233277,"version":"4.8.0"},"reference-count":91,"publisher":"American Society of Hematology","issue":"9","license":[{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,14]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>BTK inhibitors (BTKis) are established standards of care in multiple B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom macroglobulinemia. The first-generation BTKi ibrutinib demonstrated superiority over standard chemoimmunotherapy regimens in multiple randomized trials but is limited by cardiovascular side effects such as atrial fibrillation and hypertension. Second-generation BTKis have improved selectivity and demonstrate reduced rates of cardiovascular complications in 3 head-to-head ibrutinib studies. The emergence of BTK C481S mutation has led to the development of noncovalent, \u201creversible\u201d BTKis, such as pirtobrutinib, which are agnostic to the C481S mutation. However, these inhibitors are associated with resistant mutations outside the C481 hot spot. These variant non-C481 mutations are of great clinical interest because some are shared among pirtobrutinib, zanubrutinib, and acalabrutinib, with potential implications for cross resistance and treatment sequencing. Finally, BTK protein degraders with in\u00a0vitro activity against C481 and non-C481 mutations are currently in clinical development. Here, we review the evolution of therapeutic BTK-targeting and discuss future directions for clinical research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012221","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T16:27:56Z","timestamp":1710347276000},"page":"2300-2309","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":113,"title":["BTK inhibitors in CLL: second-generation drugs and beyond"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine","family":"Tam","sequence":"first","affiliation":[{"name":"1Department of Haematology, Alfred Hospital, Melbourne, VIC, Australia"},{"name":"2Haematology, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-6031","authenticated-orcid":false,"given":"Philip A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"3Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"4The Sir Peter MacCallum Department of Clinical Oncology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"issue":"6","key":"2024051415220460000_bib1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"issue":"5119","key":"2024051415220460000_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1126\/science.8332900","article-title":"Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes","volume":"261","author":"Thomas","year":"1993","journal-title":"Science"},{"issue":"6","key":"2024051415220460000_bib3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00005792-199611000-00001","article-title":"X-linked agammaglobulinemia. A clinical and molecular analysis","volume":"75","author":"Ochs","year":"1996","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2024051415220460000_bib4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.hoc.2021.03.006","article-title":"Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: beyond ibrutinib","volume":"35","author":"Lasica","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"issue":"33","key":"2024051415220460000_bib5","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024051415220460000_bib6","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1080\/10428194.2017.1375110","article-title":"Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors","volume":"59","author":"Tang","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2024051415220460000_bib7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/leu.2014.247","article-title":"Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation","volume":"29","author":"Kamel","year":"2015","journal-title":"Leukemia"},{"issue":"24","key":"2024051415220460000_bib8","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2024051415220460000_bib9","first-page":"3137","article-title":"Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders","volume":"141","author":"Thompson","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2024051415220460000_bib10","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"issue":"10","key":"2024051415220460000_bib11","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1080\/10428190701573257","article-title":"The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy","volume":"48","author":"Tam","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2024051415220460000_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"2024051415220460000_bib13","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"issue":"15","key":"2024051415220460000_bib14","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 study","volume":"26","author":"Byrd","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2024051415220460000_bib15","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"25","key":"2024051415220460000_bib16","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024051415220460000_bib17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2024051415220460000_bib18","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood.2021012315","article-title":"Ibrutinib induces durable remissions in treatment-na\u00efve patients with CLL and 17p deletion and\/or TP53 mutations","volume":"138","author":"Sivina","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2024051415220460000_bib19","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMc2005943","article-title":"Ibrutinib for chronic lymphocytic leukemia with TP53 alterations","volume":"383","author":"Ahn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024051415220460000_bib20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.15690","article-title":"Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis","volume":"184","author":"Brown","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"2024051415220460000_bib21","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","article-title":"The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis","volume":"128","author":"Leong","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2024051415220460000_bib22","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"issue":"18","key":"2024051415220460000_bib23","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/S0735-1097(21)04687-8","article-title":"Ventricular arrhythmias with ibrutinib use: a systematic review and meta analysis","volume":"77","author":"Khalid","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"18","key":"2024051415220460000_bib24","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"issue":"25","key":"2024051415220460000_bib25","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"issue":"49","key":"2024051415220460000_bib26","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1038\/sj.onc.1203958","article-title":"Signaling network of the Btk family kinases","volume":"19","author":"Qiu","year":"2000","journal-title":"Oncogene"},{"issue":"4","key":"2024051415220460000_bib27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"15 suppl","key":"2024051415220460000_bib28","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1158\/1538-7445.AM2015-2596","article-title":"Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in\u00a0vivo target coverage in chronic lymphocytic leukemia (CLL) patients","volume":"75","author":"Covey","year":"2015","journal-title":"Cancer Res"},{"issue":"1","key":"2024051415220460000_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood.2019003715","article-title":"Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib","volume":"136","author":"Sun","year":"2020","journal-title":"Blood"},{"issue":"31","key":"2024051415220460000_bib30","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"2024051415220460000_bib31","doi-asserted-by":"crossref","first-page":"720704","DOI":"10.3389\/fonc.2021.720704","article-title":"Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice","volume":"11","author":"O'Brien","year":"2021","journal-title":"Front Oncol"},{"issue":"11","key":"2024051415220460000_bib32","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/cpdd.1153","article-title":"Bioequivalence and relative bioavailability studies to assess a new acalabrutinib formulation that enables coadministration with proton-pump inhibitors","volume":"11","author":"Sharma","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"suppl 1","key":"2024051415220460000_bib33","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2023-174750","article-title":"Acalabrutinib\u00a0\u00b1 obinutuzumab vs obinutuzumab\u00a0+ chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of Elevate-TN","volume":"142","author":"Sharman","year":"2023","journal-title":"Blood"},{"issue":"10232","key":"2024051415220460000_bib34","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"2024051415220460000_bib35","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"issue":"18","key":"2024051415220460000_bib36","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A\u00a0randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2024051415220460000_bib37","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024051415220460000_bib38","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"2024051415220460000_bib39","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies","volume":"72","author":"Guha","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"2024051415220460000_bib40","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2022016953","article-title":"Ventricular arrhythmias and sudden death events following acalabrutinib initiation","volume":"140","author":"Bhat","year":"2022","journal-title":"Blood"},{"key":"2024051415220460000_bib41","author":"Tam","year":"18-22  2022"},{"issue":"6","key":"2024051415220460000_bib42","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","article-title":"Bruton tyrosine kinase inhibitors: present and future","volume":"25","author":"Burger","year":"2019","journal-title":"Cancer J"},{"issue":"24","key":"2024051415220460000_bib43","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"2024051415220460000_bib44","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"S2","key":"2024051415220460000_bib45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/hon.3164_163","article-title":"Characterization of mechanisms of resistance in previously treated chronic lymphocytic leukemia (CLL) from a head-to-head trial of acalabrutinib versus ibrutinib","volume":"41","author":"Woyach","year":"2023","journal-title":"Hematol Oncol"},{"issue":"20","key":"2024051415220460000_bib46","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance","volume":"6","author":"Blombery","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2024051415220460000_bib47","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1182\/blood-2023-173547","article-title":"Acquired mutations in patients (Pts) with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study","volume":"142","author":"Brown","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2024051415220460000_bib48","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024051415220460000_bib49","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2023-185852","article-title":"Pirtobrutinib in post-cBTKi CLL\/SLL: \u223c30\u00a0months follow-up and subgroup analysis with\/without prior BCL2i from the phase 1\/2 BRUIN study","volume":"142","author":"Woyach","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024051415220460000_bib50","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2021-147599","article-title":"Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL\/SLL: updated results from the phase 1\/2 BRUIN study","volume":"138","author":"Mato","year":"2021","journal-title":"Blood"},{"issue":"10277","key":"2024051415220460000_bib51","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"2024051415220460000_bib52","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"736","key":"2024051415220460000_bib53","doi-asserted-by":"crossref","first-page":"eabg5216","DOI":"10.1126\/scisignal.abg5216","article-title":"Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK","volume":"15","author":"Dhami","year":"2022","journal-title":"Sci Signal"},{"issue":"suppl 1","key":"2024051415220460000_bib54","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1182\/blood-2022-163596","article-title":"Efficacy and safety of nemtabrutinib, a wild-type and C481S-mutated bruton tyrosine kinase inhibitor for B-cell malignancies: updated analysis of the open-label phase 1\/2 Dose-Expansion Bellwave-001 Study","volume":"140","author":"Woyach","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2024051415220460000_bib55","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2021.280061","article-title":"Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton\u2019s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies","volume":"107","author":"Allan","year":"2021","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2024051415220460000_bib56","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2023-186432","article-title":"Initial results of a phase 1 dose escalation study of LP-168, a novel covalent and non-covalent next-generation inhibitor of Bruton's tyrosine kinase","volume":"142","author":"Woyach","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024051415220460000_bib57","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood-2022-163268","article-title":"Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders","volume":"140","author":"Montoya","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024051415220460000_bib58","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2022-164772","article-title":"NX-2127-001, a first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies","volume":"140","author":"Mato","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024051415220460000_bib59","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2023-180109","article-title":"First results from a phase 1, first-in-human study of the Bruton's tyrosine kinase (BTK) degrader Bgb-16673 in patients (Pts) with relapsed or refractory (R\/R) B-cell malignancies (BGB-16673-101)","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2024051415220460000_bib60","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"2024051415220460000_bib61","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"2024051415220460000_bib62","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"2024051415220460000_bib63","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"22","key":"2024051415220460000_bib64","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024051415220460000_bib65","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol"},{"issue":"34","key":"2024051415220460000_bib67","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the Randomized Phase II CAPTIVATE Study","volume":"39","author":"Wierda","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"2024051415220460000_bib75","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024051415220460000_bib78","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"issue":"suppl 16","key":"2024051415220460000_bib79","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1200\/JCO.2022.40.16_suppl.7519","article-title":"Fixed-duration (FD) ibrutinib (I)\u00a0+ venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study","volume":"40","author":"Wierda","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2024051415220460000_bib80","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/blood-2022-156070","article-title":"Residual disease kinetics among patients with high-risk factors treated with first-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): the Glow study","volume":"140","author":"Niemann","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2024051415220460000_bib81","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"36","key":"2024051415220460000_bib82","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"2024051415220460000_bib66","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"31","key":"2024051415220460000_bib68","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1200\/JCO.20.00491","article-title":"Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-na\u00efve and relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Rogers","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2024051415220460000_bib69","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.2023020013","article-title":"Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)\/TP53mut","volume":"142","author":"Huber","year":"2023","journal-title":"Blood"},{"issue":"19","key":"2024051415220460000_bib70","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024051415220460000_bib71","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2022-168003","article-title":"Updated results from a multicenter, phase 2 study of acalabrutinib, venetoclax, obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high-risk disease","volume":"140","author":"Ryan","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2024051415220460000_bib72","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S1470-2045(21)00455-1","article-title":"Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study","volume":"22","author":"Davids","year":"2021","journal-title":"Lancet Oncol"},{"issue":"S2","key":"2024051415220460000_bib73","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hon.3163_153","article-title":"Long-term follow-up of multicenter phase II Trial of zanubrutinib, obinutuzumab and venetoclax (BOVEN) in previously untreated patients with CLL\/SLL","volume":"41","author":"Soumerai","year":"2023","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"2024051415220460000_bib74","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood-2019-131732","article-title":"Combined ibrutinib and venetoclax in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL)","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2024051415220460000_bib76","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/blood-2022-166700","article-title":"MRD4 eradication at 6\u00a0months and early clearance of MRD with combination of ibrutinib plus venetoclax results in sustained clinical and MRD responses: exploratory analysis of the Blood Cancer UK TAP Clarity Study","volume":"140","author":"Munir","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2024051415220460000_bib77","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S1470-2045(22)00220-0","article-title":"Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141\/VISION): primary analysis of an open-label, randomised, phase 2 trial","volume":"23","author":"Kater","year":"2022","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2024051415220460000_bib83","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood-2023-187128","article-title":"Relapse after first-line fixed duration ibrutinib\u00a0+ venetoclax: high response rates to ibrutinib retreatment and absence of BTK mutations in patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) with up to 5 years of follow-up in the phase 2 Captivate study","volume":"142","author":"Ghia","year":"2023","journal-title":"Blood"},{"issue":"16 suppl","key":"2024051415220460000_bib84","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1200\/JCO.2023.41.16_suppl.7535","article-title":"Fixed-duration ibrutinib\u00a0+ venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study","volume":"41","author":"Barr","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024051415220460000_bib85","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024051415220460000_bib86","first-page":"1","article-title":"Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon","volume":"64","author":"Lew","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"2024051415220460000_bib87","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2024051415220460000_bib88","first-page":"1","article-title":"Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with veneto-clax-based regimens","volume":"64","author":"Hampel","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2024051415220460000_bib89","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024051415220460000_bib90","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1182\/blood-2018-99-115418","article-title":"Prospective clinical trial of anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia shows a high response rate","volume":"132","author":"Gill","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2024051415220460000_bib91","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-140622","article-title":"Transcend CLL 004: phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL)","volume":"136","author":"Wierda","year":"2020","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/9\/2300\/2225009\/blooda_adv-2023-012221-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/9\/2300\/2225009\/blooda_adv-2023-012221-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T15:23:22Z","timestamp":1715700202000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/9\/2300\/515303\/BTK-inhibitors-in-CLL-second-generation-drugs-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":91,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,5,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012221","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]}}}